CTI BioPharma Market Share Analysis for June 2026

Together with Sanofi, we intend to donate up to 1 billion international units (IU) of factor replacement for use in developing countries. More than 75 per cent of people with haemophilia around the world have limited or no access to diagnosis and treatment, particularly in the developing world. People with severe haemophilia in these countries often do not survive to adulthood; for those who do, life often entails severe disability, isolation, and chronic pain. The World Federation of Hemophilia (WFH) Humanitarian Aid Program helps address the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. The program has supported 112 countries since its inception in 1996. Read about the progress made by WFH during 2024 in the Humanitarian Aid Impact Report 2024.WFH's Humanitarian Aid Program provides a more predictable and sustainable supply of medicines, enabling patients to have reliable access to treatment and care. In addition, training programs for care providers and patients are needed to develop the local capacity for better diagnosis and follow up treatment and enable changes that are sustainable in the long term.